Roche to Expand Respiratory Role With InterMune Puchase

Roche Holding AG, the world’s largest maker of cancer drugs, is strengthening its portfolio of medicines for respiratory ailments with an agreement to buy InterMune Inc. for $8.3 billion in cash.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.